Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
The three substrates of this enzyme are (S)-lactaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are (S)-lactic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-lactaldehyde:NAD+ oxidoreductase. Other names in common use include L-lactaldehyde:NAD+ oxidoreductase, and nicotinamide adenine dinucleotide (NAD+)-linked dehydrogenase. This enzyme participates in pyruvate metabolism.
== Anatomy in visual arts == Gross anatomy has become a key part of visual arts. Basic concepts of how muscles and bones function and deform with movement is key to drawing, painting or animating a human figure. Many books such as Human Anatomy for Artists: The Elements of Form, are written as a guide to drawing the human body anatomically correctly. Leonardo da Vinci sought to improve his art through a better understanding of human anatomy. In the process he advanced both human anatomy and its representation in art. Because the structure of a living organism is complex, anatomy is organized by levels, from the smallest components of cells to the largest organs and their relationship to other organs.
In general, action potentials that reach the synaptic knobs cause a neurotransmitter to be released into the synaptic cleft. Neurotransmitters are small molecules that may open ion channels in the postsynaptic cell; most axons have the same neurotransmitter at all of their termini. The arrival of the action potential opens voltage-sensitive calcium channels in the presynaptic membrane; the influx of calcium causes vesicles filled with neurotransmitter to migrate to the cell's surface and release their contents into the synaptic cleft. This complex process is inhibited by the neurotoxins tetanospasmin and botulinum toxin, which are responsible for tetanus and botulism, respectively.
== History and discovery == The discovery for aggrecanases initially came from the study of cartilage and the way it degraded depending on it conditions. Scientists were attempting to find the difference in cartilage from its normal state to its diseased state. The initial analysis determined the matrix metalloproteinases could cleave the cartilage at a specific site. The site as within the interlobular domain it was in between the G1 and G2 regions. Upon further experimentation in 1991, the cartilage was treated with interleukin-1, an inflammatory mediator. This went against the initial findings because the split happened in a new location. This new discovery allowed scientist to understand there was another enzyme that was responsible, aggrecanase. Through further experimentation aggrecanse was continually detected particularly in relation to inflammatory arthritis and osteoarthritis. The first successfully identified enzyme was ADAMTS4, an aggrecanase. As time went on the enzyme was determined to be a part of a zinc dependent family, the ADAMTS family. More enzymes were discovered, ADAMTS5 and ADAMRS1. All of the enzymes in the ADAMTS family were exhibiting similar activity. They were all functioning within the cartilage as mediators.
Crystallography is a technique that characterizes the chemical structure of materials at the atomic level by analyzing the diffraction patterns of electromagnetic radiation or particles that have been deflected by atoms in the material. X-rays are most commonly used. From the raw data, the relative placement of atoms in space may be determined.
Sources: en.wikipedia.org
During the early 20th century, the Russian movement of Cosmism, as represented by Nikolai Fyodorovich Fyodorov, envisioned scientific resurrection of dead people. The idea was so popular that, after Vladimir Lenin's death, Leonid Krasin and Alexander Bogdanov suggested to cryonically preserve his body and brain in order to revive him in the future. Necessary equipment was purchased abroad, but for a variety of reasons the plan was not realized. Instead his body was embalmed and placed on permanent exhibition in the Lenin Mausoleum in Moscow, where it is displayed to this day. The mausoleum itself was modeled by Alexey Shchusev on the Pyramid of Djoser and the Tomb of Cyrus.
In 2022, Newsom was elected to a second term, defeating Republican state senator Brian Dahle with 59.2% of the vote. This was a smaller margin of victory than in 2018, and the first time since 2010 that the Democratic gubernatorial nominee did not win at least 60% of the vote.
== Clinical significance == LPS exposure induces LBP production. LBP is synthesized by the liver, adipose tissue, and intestinal cells. Dietary glucose and saturated fats acutely increase plasma LBP. The proinflammatory activity of plasma LPS is increased by LBP, which is higher in obesity. Plasma LBP is used as a better biomarker of plasma LPS than LPS itself due to the short half-life of LPS.
=== START college savings plan === In 1997, Louisiana launched its Student Tuition Assistance and Revenue Trust Savings Program to allow people to start a 529 plan to save for their children's education. As treasurer, Kennedy expanded five new investment options to give parents the choice of investing in the stock market in addition to the fixed returned securities options. He also put these investment options online to make it easier for parents to watch and manage their investments. During Kennedy's tenure, Louisiana's START program was ranked fifth-best in the nation.
Sources: en.wikipedia.org
== History == Use of barrier membranes to direct bone regeneration was first described in the context of orthopaedic research 1959. The theoretical principles basic to guided tissue regeneration were developed by Melcher in 1976, who outlined the necessity of excluding unwanted cell lines from healing sites to allow growth of desired tissues. Based on positive clinical results of regeneration in periodontology research in the 1980s, research began to focus on the potential for re-building alveolar bone defects using guided bone regeneration. The theory of Guided tissue regeneration has been challenged in dentistry. The GBR principle was first examined by Dahlin et al. in 1988 on rats. In 1988, Swiss oral and maxillofacial surgeon Daniel Buser performed one of the first documented Guided Bone Regeneration procedures at the University of Bern. The selective ingrowth of bone-forming cells into a bone defect region could be improved if the adjacent tissue is kept away with a membrane; this was confirmed in a study by Kostopoulos and Karring in 1994. GBR can be used for bone regeneration on exposed implant coils .
The lotus roots grow in pond or river bottom soil, while the leaves float on the water's surface or are held well above it. The leaf stalks (petioles) can be up to 200 cm (6 ft 7 in) long, allowing the plant to grow in water to that depth. The peltate leaf blade or lamina can have a diameter of 80–100 cm (2 ft 7 in – 3 ft 3 in). The leaves are spaced up to 2 m (6 ft 7 in) apart along the rhizome, which can grow as much as 20 m (66 ft) in one year. The internodes are not cylindrical but swollen in the middle.
World War II caused a pause in palaeontological research; after the war, research attention was also diverted increasingly to fossil mammals rather than dinosaurs, which were seen as sluggish and cold-blooded. At the end of the 1960s, however, the field of dinosaur research experienced a surge in activity that remains ongoing. Several seminal studies led to this activity. First, John Ostrom discovered the bird-like dromaeosaurid theropod Deinonychus and described it in 1969. Its anatomy indicated that it was an active predator that was likely warm-blooded, in marked contrast to the then-prevailing image of dinosaurs. Concurrently, Robert T. Bakker published a series of studies that likewise argued for active lifestyles in dinosaurs based on anatomical and ecological evidence (see § Physiology), which were subsequently summarized in his 1986 book The Dinosaur Heresies.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.